Key Highlights
- AOTI Inc LSE:AOTI gained 14.04% on 18 August 2026, putting the specialist healthcare technology company firmly in focus.
- The company develops TWO₂ topical oxygen therapy, aimed at helping patients with chronic and non-healing wounds.
- The biggest catalyst for AOTI remains the proposed nationwide US Medicare coverage determination for topical oxygen therapy in qualifying diabetic foot ulcers.
- The proposed coverage would potentially give AOTI access to approximately 69 million Medicare enrollees, significantly expanding its addressable US market.
- AOTI reported approximately $35 million of first-half 2026 revenue, representing 10% reported growth and 18% underlying growth excluding Arizona Medicaid.
- The company ended the first half with approximately $13.8 million of cash and $6.3 million of net debt.
- AOTI said its TWO₂ therapy already has more than 75% market share within the topical oxygen therapy segment.
- Investors are now watching the Medicare coverage process, commercial adoption, Medicaid expansion, Revenue growth and the company's ability to convert regulatory progress into stronger financial performance.
Why Is AOTI LSE:AOTI in Focus on 18 August 2026?
AOTI Inc LSE:AOTI rose 14.04% on 18 August 2026, putting the specialist medical technology company among the healthcare stocks attracting significant investor attention.
The move comes after a major development in July fundamentally changed the potential size of AOTI's US market.
The US Centers for Medicare & Medicaid Services issued a proposed Local Coverage Determination supporting topical oxygen therapy for Medicare beneficiaries with diabetic foot ulcers that have failed to heal after four consecutive weeks of optimised care.
For AOTI, this is potentially transformative because the company has spent years building clinical evidence, payer relationships and commercial infrastructure around its TWO₂ therapy.
The proposed coverage does not mean the final national reimbursement decision has already been implemented. There is a public-comment process followed by further review before a final determination.
Nevertheless, the proposal significantly reduces one of the biggest uncertainties surrounding AOTI's long-term US growth opportunity.
That is why the stock remains firmly on the watchlist after the latest 14.04% gain.
What Does AOTI Inc Actually Do?
AOTI is a medical technology company focused on outcomes-based wound care delivered in the home.
Its flagship TWO₂ therapy is a topical oxygen treatment designed to support healing of chronic and difficult-to-heal wounds.
The company's strategy is particularly focused on diabetic foot ulcers, which represent a major healthcare burden in the United States and globally.
Diabetic foot ulcers can take a long time to heal and can result in infections, hospitalisation and, in severe cases, amputation.
AOTI's proposition is therefore based on improving healing outcomes while potentially reducing the wider healthcare costs associated with chronic wounds.
The company's Business model has historically been constrained by payer coverage and reimbursement.
That makes the proposed nationwide Medicare coverage particularly important.
If coverage becomes final, AOTI would have a much larger addressable population for its therapy.
Why Is Medicare Coverage So Important for LSE:AOTI?
Medicare is central to the AOTI Investment story because of the size and characteristics of the eligible population.
AOTI estimates that the proposed coverage could provide access to approximately 69 million Medicare enrollees.
This is considerably larger than the company's existing addressable market through selected Medicaid programmes, Veterans Administration business and commercial payer relationships.
The Medicare opportunity is also strategically important because a national coverage decision could help establish a stronger reimbursement precedent across other parts of the US healthcare system.
AOTI has indicated that broader Medicare coverage could accelerate access to Medicaid and commercial payer populations.
That creates a potential multiplier effect.
The direct opportunity would be Medicare reimbursement, while the indirect opportunity could involve improved acceptance of topical oxygen therapy across other healthcare segments.
For investors, this is one of the most important reasons AOTI's valuation narrative has changed during 2026.
What Exactly Did CMS Propose?
The proposed coverage determination indicates that topical oxygen therapy is reasonable and necessary for Medicare beneficiaries suffering from diabetic foot ulcers that have failed to heal after four consecutive weeks of optimised diabetic foot-ulcer care.
The proposal is nationwide rather than restricted to a single state.
That distinction is crucial.
AOTI's existing US growth has been affected by the fragmented nature of healthcare reimbursement, with different payer and state-level arrangements creating uncertainty around access.
A nationwide Medicare framework could provide substantially greater visibility.
The proposed determination is still subject to the formal process, meaning investors should not treat it as equivalent to final coverage.
The company has indicated that after the 45-day public-comment period, CMS is expected to finalise the determination within the permitted review period.
Therefore, the timing and exact terms of the final coverage decision remain important variables.
Why Did AOTI Shares Rise 14.04% on 18 August 2026?
The 14.04% increase on 18 August 2026 comes against a backdrop of several important developments rather than a single newly announced event on that day.
The biggest fundamental catalyst remains the proposed Medicare coverage decision announced in July.
That announcement dramatically increased the potential addressable market for TWO₂.
AOTI subsequently reported first-half trading data showing approximately $35 million of revenue, representing 10% year-on-year growth, or 18% growth when excluding Arizona Medicaid.
The combination of regulatory progress and resilient underlying trading provides investors with two important pieces of the growth story.
The regulatory development expands the potential market.
The financial performance demonstrates that AOTI already has a commercial business before Medicare coverage is fully established.
That combination can generate substantial investor interest in a small-cap healthcare technology company.
What Were AOTI's First-Half 2026 Results?
AOTI reported approximately $35 million of revenue in the first half of 2026, representing 10% reported year-on-year growth.
Underlying growth excluding Arizona Medicaid was approximately 18%.
The distinction is important because Arizona Medicaid has been a significant source of disruption.
AOTI previously decided to stop enrolling new Arizona Medicaid patients after reimbursement issues created financial uncertainty.
Consequently, reported revenue growth does not fully capture the underlying performance of the continuing business.
The company's Veterans Administration business remained an important contributor, while Medicaid revenue excluding Arizona also demonstrated strong underlying growth.
Investors are therefore likely to focus increasingly on the quality of revenue growth rather than simply the headline percentage.
Why Does Arizona Medicaid Matter?
Arizona Medicaid has been one of the major short-term challenges facing AOTI.
The company has previously explained that reimbursement difficulties in Arizona affected cash collection and working capital.
AOTI ultimately stopped enrolling new Arizona Medicaid patients from April 2026.
That decision reduces exposure to a problematic revenue stream but also means the company has had to absorb a near-term impact on reported growth.
The strategy is therefore a trade-off.
AOTI is sacrificing some lower-quality or uncertain revenue in order to concentrate resources on markets where reimbursement visibility is stronger.
That makes the company's underlying growth rate more important.
If revenue continues to expand through the Veterans Administration, New York Medicaid and other commercial channels while the company prepares for Medicare, the Arizona Withdrawal could eventually become less significant.
How Strong Is AOTI's TWO₂ Market Position?
AOTI has positioned TWO₂ as the leading product in the topical oxygen therapy segment.
The company says it holds more than 75% market share in the category.
That existing market position is particularly relevant if Medicare coverage becomes final.
A company entering a newly reimbursed market with no commercial infrastructure would need to build sales channels, clinical relationships and customer awareness from scratch.
AOTI already has an established product, clinical evidence base and commercial presence.
That could allow it to respond more quickly to an expanded reimbursement environment.
The company's advantage will ultimately depend on how effectively it can scale treatment delivery and manage the additional demand.
Why Is the Clinical Evidence Important?
Healthcare reimbursement decisions depend heavily on evidence.
AOTI has spent considerable effort developing a clinical and health-economic evidence base supporting TWO₂.
The company has previously highlighted evidence from randomised controlled trials and real-world studies, along with endorsements and reimbursement-related decisions in several markets.
In 2025, TWO₂ received supportive decisions and recommendations in the UK and Germany, while the company also highlighted progress in US payer access.
The CMS proposal represents a particularly important validation because it relates directly to the US Medicare population.
However, investors should continue to distinguish between clinical evidence supporting a therapy and the ultimate commercial outcome.
Coverage does not guarantee that every eligible patient will receive the therapy or that AOTI will capture the entire potential market.
Sales execution, physician adoption, reimbursement rates and patient eligibility will all influence the eventual financial impact.
Could Medicare Coverage Transform AOTI's Revenue Growth?
Potentially, yes.
The company currently generates revenue through several channels, including the Veterans Administration, Medicaid and commercial healthcare relationships.
Medicare coverage would add a much larger national population.
The opportunity is particularly significant because diabetic foot ulcers are associated with diabetes, a condition affecting a large proportion of the older US population.
AOTI has highlighted the scale of the Medicare population and the prevalence of diabetes within it.
If final coverage is secured and physicians increasingly adopt TWO₂, the company's addressable market could expand substantially.
However, the financial impact would likely build over time rather than appear instantly.
New reimbursement policies need to be implemented, healthcare providers need to understand the coverage criteria, patients need to be identified and treatment capacity needs to scale.
The market is therefore watching not only the final decision but also what happens after coverage becomes effective.
What Are Investors Watching After the 14.04% Rally?
The first major Factor is the final Medicare coverage determination.
This remains the most important regulatory catalyst.
The second is the timing of reimbursement implementation.
A favourable decision is only the beginning. Investors will want to see how quickly reimbursement translates into actual treatment volumes.
The third is Medicare patient growth.
AOTI's ability to convert the newly accessible population into revenue will determine the commercial significance of the policy change.
The fourth is Medicaid expansion.
AOTI expects broader Medicare coverage to help accelerate access in other payer segments.
The fifth is commercial payer adoption.
Greater acceptance among private insurers could materially increase the company's addressable market.
The sixth is revenue growth and profitability.
Investors will want to see whether higher market access translates into accelerating revenue and operating leverage.
What Is the Financial Position of AOTI?
AOTI ended the first half of 2026 with approximately $13.8 million in cash and $6.3 million of net debt.
This represents an important improvement in the company's financial flexibility compared with the earlier period of elevated working-capital pressure.
The company generated approximately $35 million of first-half revenue, providing a meaningful commercial base from which to pursue future expansion.
Nevertheless, scaling nationally across Medicare could require additional investment.
AOTI will need to manage sales capacity, patient onboarding, treatment logistics and Working Capital as market access expands.
The ability to achieve growth without creating disproportionate operating costs will therefore become increasingly important.
Why Is the US Healthcare Market Still a Risk for AOTI?
Despite the positive Medicare development, AOTI remains exposed to the complexities of the US healthcare reimbursement system.
The company experienced significant disruption from US healthcare policy changes during 2025 and 2026.
Arizona Medicaid demonstrated how reimbursement delays and policy changes can affect revenue quality and cash collection.
The proposed Medicare determination reduces one area of uncertainty but does not eliminate all reimbursement risks.
The final coverage criteria, reimbursement rates, implementation timetable and subsequent payer decisions will all influence commercial performance.
Investors therefore need to monitor both regulatory progress and financial execution.
Could AOTI Benefit From a Broader Wound-Care Market Opportunity?
The opportunity extends beyond diabetic foot ulcers.
AOTI's platform is designed around chronic and non-healing wounds, while the company has been developing a broader outcomes-based care proposition.
The Medicare proposal initially focuses on diabetic foot ulcers that meet specific treatment criteria.
However, a successful national coverage framework could potentially establish a stronger clinical and reimbursement precedent for topical oxygen therapy in other wound-care categories.
That is why the company describes the development as potentially transformational rather than simply another incremental reimbursement win.
The longer-term opportunity depends on whether the therapy can achieve wider payer acceptance across additional patient groups.
What Could Drive the Next Major Move in LSE:AOTI?
The next major catalyst is likely to be progress toward final Medicare coverage.
A positive final determination could remove a major uncertainty and give investors greater visibility over the potential size of the US market.
Further catalysts could include strong second-half revenue growth, increased Veterans Administration demand, new commercial payer coverage and accelerated Medicaid adoption.
Evidence of rapid customer or patient growth following expanded coverage would be particularly significant.
Investors may also watch cash generation and margins because a larger addressable market does not automatically guarantee higher profitability.
The company needs to demonstrate that commercial expansion can generate attractive economics.
What Are the Main Risks Around LSE:AOTI?
The first risk is regulatory timing.
The proposed Medicare coverage still has to pass through the formal process.
The second is commercial adoption.
Coverage does not guarantee immediate physician or patient uptake.
The third is reimbursement risk.
The final reimbursement rate and coverage criteria will influence the Economics of treatment.
The fourth is working-capital risk.
AOTI has already experienced difficulties associated with delayed reimbursement in Arizona.
The fifth is execution risk.
Scaling the business across a much larger US population will require additional commercial and operational capacity.
The sixth is share-price volatility.
The 14.04% one-day move demonstrates how quickly sentiment can change around a small-cap healthcare technology company.
What Should Investors Watch Through the Rest of 2026?
Investors tracking LSE:AOTI should focus on several measurable developments:
- Progress toward the final Medicare coverage determination
- The implementation timetable following the final decision
- Medicare reimbursement criteria
- Second-half revenue growth
- Veterans Administration performance
- Underlying Medicaid growth excluding Arizona
- Commercial payer adoption
- Patient treatment volumes
- TWO₂ market share
- Cash generation
- Net debt
- Operating margins
- Evidence of broader wound-care adoption
The combination of regulatory and commercial milestones makes the remainder of 2026 an important period for AOTI.
What Is the Outlook for AOTI After the 18 August Rally?
AOTI enters the second half of 2026 with a considerably larger potential US opportunity than it had at the beginning of the year.
The proposed nationwide Medicare coverage determination represents the biggest strategic development in the company's recent history.
The company is already generating tens of millions of dollars in annual revenue, has established a significant position in topical oxygen therapy and has built clinical and commercial infrastructure around TWO₂.
The challenge now is execution.
A favourable final Medicare determination would be important, but the ultimate test will be whether AOTI can turn reimbursement access into patient growth, revenue acceleration and sustainable profitability.
The 14.04% rise on 18 August 2026 therefore reflects a market increasingly focused on the potential transition from a specialist healthcare technology company serving selected payer markets to a business with access to a much broader national US reimbursement opportunity.
What Is the Main Takeaway From the AOTI Share Price Surge?
AOTI Inc LSE:AOTI gained 14.04% on 18 August 2026, bringing renewed attention to one of the UK's more specialised healthcare technology stocks.
The company's investment story has changed significantly following the proposed nationwide US Medicare coverage determination for topical oxygen therapy.
AOTI's TWO₂ therapy is already established within the topical oxygen therapy market, while first-half 2026 revenue reached approximately $35 million, with underlying growth of 18% excluding Arizona Medicaid.
The proposed Medicare coverage could potentially open access to approximately 69 million beneficiaries, creating a substantially larger addressable market.
The most important question now is whether the proposed policy becomes final and how quickly AOTI can convert expanded reimbursement into commercial growth.
Investors are therefore watching the regulatory process, reimbursement implementation, patient adoption, revenue growth, margins and cash generation.
For LSE:AOTI, the latest rally highlights a potentially transformational opportunity, but the next stage of the story will depend on execution rather than regulatory headlines alone.






Please wait processing your request...